Intellectual Property Magazine
Covid collaborators
Karen Sebaski examineshow companies can avoid or prepare for patent disputes when teaming up to accelerate vaccine developments
Karen Sebaski- Holwell Shuster &Goldberg
Without a doubt, the race to develop safe andeffective vaccines to combat the novel Covid-19 virus is an unprecedented,global
effort. At present, more than 165 vaccines are in development worldwide,27 of which are in human trials.
1 And although the aspirationaltimeline for a Covid-19 vaccine is 12-to-18 months, the typical timeline todevelop an average
vaccine candidate is just over 10 years.
2